The move comes less than three years after the Gaithersburg biotech spun out of MedImmune.
Image: Viela Bio CEO Bing Yao, pictured here on the company’s IPO day at the Nasdaq. LIBBY GREENE
{iframe}https://www.bizjournals.com/washington/news/2021/02/01/viela-bio-to-be-acquired-for-3-1-billion.html{/iframe}